艾灸跟失智|艾灸對認知障礙的療效：系統回顧與動物實驗的整合分析

Integr Med Res. 2020 Oct 14;10(2):100680. doi: 10.1016/j.imr.2020.100680

Moxibustion for cognitive impairment: a systematic review and meta-analysis of animal studies

Sungmin Aum a, Seon Choe b, Mudan Cai c, Ui Min Jerng d,⁎, Jun-Hwan Lee c,⁎

• Author information

• Article notes

• Copyright and License information

PMCID: PMC7972968  PMID: 33747784

Abstract

Background

Cognitive impairment is an age-dependent chronic disorder that exponentially worsens with age; however, its treatment is mostly symptomatic. Moxibustion is widely accepted in East Asia as a treatment for cognitive impairment. This systematic review aimed to verify the efficacy and underlying mechanism of moxibustion in treating cognitive impairment.

Methods

Sixteen trials involving 324 animals obtained from MEDLINE (PubMed), EMBASE, the Cochrane library, the Chinese National Knowledge Infrastructure, Wan-Fang, Cqvip, the Korean Studies Information Service System, and the Oriental Medicine Advanced Searching Integrated System met the inclusion criteria. We extracted the results of behavioral tests and immunohistochemical biomarkers from the included articles and evaluated the risk of bias and reporting quality.

Results

The moxibustion group showed significantly decreased escape latency, increased crossing times, and prolonged dwelling times in the Morris water maze test. There was a significantly enhanced latency period and reduced error time in the step-down test and nerve behavior score. The effects of moxibustion were found to be mediated by suppression of oxidative stress and apoptosis, modulation of inflammation and Aβ genesis activation of vascular endothelial growth factor, and adjustment of metabolites in the tricarboxylic acid cycle and fatty acid metabolism.

Conclusion

Our results demonstrated the therapeutic efficacy of moxibustion on cognitive impairment and suggested the putative mechanism. However, considering the small number of included studies, high bias risk, low reporting quality, and the limitations of animal experimentation, our results need to be confirmed by more detailed studies.

Keywords: Animal experimentation, Cognitive impairment, Dementia, Moxibustion, Systematic review

1. Introduction

Cognitive impairment is an age-dependent chronic disorder1; globally, the number of patients is expected to reach 82 million in 2030 and 152 million in 2050.2 Alzheimer disease (AD) is the most common type of cognitive impairment,3 accounting for 60–80% of all cases,2,4 which is characterized by the accumulation of Aβ peptides, senile plaques, and intracellular neurofibrillary tangles (NFT), related to neuronal damage and premature neuronal death.4 Vascular dementia (VD) is the second most common type of cognitive impairment, which is driven by complex factors reducing cerebral blood flow and causing oxidative stress, resulting in cerebral ischemia.5

Despite the growing need for proper management of cognitive impairment in aging societies, the available therapeutic options are still mostly symptomatic, providing short-term benefit for specific condition, with a risk of adverse drug reactions (ADRs).6

Moxibustion is a widely used therapy in Eastern Asia for more than 2500 years.7,8 Moxibustion entails stimulating acupoints on the body by burning herb leaves directly (attaching moxa cones to the skin) or indirectly (interposing a substance such as ginger between the moxa cones and the skin) to transmit heat stimulation8,9 and induce pharmacological action via herbal components.10,11

In addition to its wide range of use for pain relief12,13 and inflammation control,14,15 moxibustion has been recognized as a suitable treatment for cognitive impairment, with several recent studies indicating its efficacy in patients with dementia.16,17

Acupuncture, another representative traditional Chinese medicine treatment, has been reported to be effective in cognitive enhancement, with supporting evidence from several systematic reviews (SRs),18,19,20 suggesting that its potential mechanism involves suppression of oxidative stress and neuroinflammation and modulation of glucose metabolism5 and neuronal signaling pathways.21

However, compared with acupuncture studies, the therapeutic efficacy of moxibustion for cognitive impairment has not been fully validated. Although a previous study has reported the action of moxibustion in preventing cognitive impairment,22 information on the overall therapeutic effect of moxibustion was limited, as it was focused on prevention. This SR aimed to evaluate the efficacy of moxibustion in treating cognitive impairment through a meta-analysis of animal studies. We also examined the underlying mechanisms and the quality of the supporting evidence.

2. Methods

2.1. Study search and selection

We used search terms consisting of variants of “cognitive impairment” for the target disease, “moxibustion” for the intervention, and “animal study.” The following databases were searched: MEDLINE (PubMed), EMBASE, and the Cochrane library (English language); the Chinese National Knowledge Infrastructure, Wan-Fang, and Cqvip Database (Chinese language); the Korean Studies Information Service System and Oriental Medicine Advanced Searching Integrated System (Korean language). We searched studies published from the time of inception of each database to January 2019.

2.2. Inclusion and exclusion criteria

We included animal studies that conducted randomized controlled trials on moxibustion as an intervention for cognitive disorders. We did not discriminate between different types of cognitive impairment including AD and VD. The search terms we used for describing cognitive impairment are provided in Supplementary material. All rodent models developed for any type of cognitive impairment were included.

Although we included all types of moxibustion, we excluded studies that used combined treatments. Furthermore, in the control group, we only included studies that used cognitively impaired animals without any interventions. Regarding outcome measurements, we included results from behavioral tests, immunohistochemistry, and electron microscopic analyses.

Two reviewers (SMA and SC) independently selected and evaluated the studies and subsequently discussed for confirmation. Conflicts were resolved by consulting a third reviewer (UMJ) to reach a consensus. We used the eligible studies to extract data in a standardized form suitable for animal study design as follows: study design, research institute, methodological details, procedure compatibility (performing of randomization and blinding), and therapeutic characteristics of moxibustion. Regarding measurement outcomes, we defined the primary outcomes as behavioral test results and the secondary outcomes as immunohistochemical results. For studies where data was only graphically presented, we attempted to contact the corresponding author; if unsuccessful, we extracted the data by scaling the graph using the GetData graph digitizer version 2.26.0.20 (copyright 2001–2013; S. Fedorov). Details of the included studies are shown in Table 1.

Table 1.

Characteristics of the included studies in animal model and treatment.

Study

Animal model

Treatment

Species

Age (months)

Weight (g)

Sample size

Target Disease

Acupoints

Moxa diameter (mm)

Duration (min)

Treatment period

Moxa (M, F)

Control (M, F)

Du 26

Wistar rat

12

500 ± 20

(10,0)

(10,0)

AD

GV20, BL23

6

15

14 times for 14 days

Liu 33

ApoE(−/−) mice

2

27 ∼ 29

(11,0)

(11,0)

AD

CV8

20∼30

20

72 times for 78 days

Wang 27

SD rat

15

350 ∼450

(10,0)

(10,0)

AD

GV20, BL23, ST36

NR

5

18 times for 21 days

Wang 28

SD rat

15

350 ∼450

(10,0)

(10,0)

AD

GV20, BL23, ST36

8

5

18 times for 21 days

Wang 29

SD rat

15

350 ∼450

(10,0)

(10,0)

AD

GV20, BL23, ST36

NR

5

18 times for 21 days

Jiang 31

SD rat

2

300 ± 30

(11,0)

(10,0)

AD

GV20, GV4, GV1, CV4

10

3 or 7*

10 times for 30 days

Wang 34

Wistar rat

NR

300 ± 30

(12,0)

(12,0)

VD

GV20, GV24, GV14

NR

20

30 times for 31 days

Wang 37

Wistar rat

10

300 ± 30

(12,0)

(12,0)

VD

GV20, GV24, GV14

2∼3

20

30 times for 31 days

Zhu 30

SD rat

NR

NR

(12,0)

(12,0)

AD

GV20, GV16, GV14

20

20

15 times for 15 days

Wang 35

SD rat

NR

250 ± 10

(7.0)

(7,0)

VD

GV20, GV24, GV14

5

20

30 times for 30 days

Weilan38

Wistar rat

NR

220 ± 20

(7,0)

(7,0)

VD

GV20, GV16, ST36, GB20

NR

3 Zhuang

24 times for 27 days

Luo 40

Wistar rat

NR

280 ± 20

(10,0)

(10,0)

VD

CV6, CV12, CV17, SP10, TE5, ST36

5

3 or 4 Zhuang

24 times for 27 days

Zhang 36

Wistar rat

10

250 ± 50

(8,0)

(8,0)

VD

GV20, GV24, GV14

15

20

30 times for 31 days

Xiao 7

SD rat

2

350 ∼400

(10,0)

(10,0)

AD

KI6, TE5, GB41, PC6, SP4, SI3, BL62, LU7

NR

9 Zhuang

35 times for 35 days

Yu 32

APP/PS1mice

6

NR

(12.0)

(12,0)

AD

CV4

20

15

48 times for 55 days

Zhu 39

SD rat

NR

200 ∼250

(10,0)

(10,0)

VD

GV14, GV4, CV4

NR

15

24 times for 27 days

Open in a new tab

Abbreviations: SDS, prague-Dawley; ApoE−/−, apolipoprotein E-deficient; APP/PS1, Amyloid precursor protein/presenilin-1 transgenic; M, male; F, female; AD, Alzheimer’s disease; DB, database; VD, vascular dementia; NR, not reported; NA, not applicable.

*Jiang31 treated all participants using moxibustion for 3 min except GV20 which received moxibustion for 7 min.

2.3. Study assessment and analysis

We evaluated the overall potential bias in the included studies based on the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES) study quality checklist,23 as suggested by CAMARADES24 for reporting animal data from experimental studies. The reporting quality of each study was evaluated according to the Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines checklist.25

In the behavioral test, decreased escape latency in the Morris water maze (MWM) test suggests restored cognitive function, which is indicated by faster learning, maintaining a better score on average, and achieving a superior final score; meanwhile, increased cross and dwelling times from the target probe test suggest prolonged memory. Assessment of the step-down test results and neuronal behavior scores indicated a beneficial effect in extending the latency period and shortening error times.

The results of behavioral tests obtained by means and standard errors were synthesized, and meta-analyses were conducted using a random effect model, the RevMan version 5.3 (released on June 13, 2014, Cochrane Collaboration).

3. Results

3.1. Characteristics of included studies

3.1.1. Study screening

Based on our electronic search criteria, we retrieved 3474 articles. After removing duplicate studies, the titles and abstracts of 3109 studies were screened and 296 articles were selected for in-depth screening of the full text. Finally, 16 original articles met our inclusion criteria, of which five could be quantitatively synthesized. Among the 16 articles, two were dissertations not published in peer-review journals. A diagram of the study selection process is shown in Fig. 1.

Fig. 1.

Open in a new tab

PRISMA flow diagram for selecting related studies.

3.1.2. Fundamental study characteristics: animals

The 16 original research studies included in our analysis used a total of 324 rats and mice (age: 2–15 months; weight: 200–520 g [rats], 27–29 g [mice]). Nine studies established an AD model; among them, four studies injected Aβ (Aβ1–4226 or Aβ25–3527, 28, 29), three studies injected chemical toxin (d-galactose7,30 or streptozotocin31) into the hippocampus, and two studies established transgenic mice (amyloid precursor protein [APP]/presenilin 1 [PS1]), double-transgenic mice,32 or apolipoprotein E-deficient (ApoE−/−) mice.33 Seven studies established VD models by performing four-vessel occlusion,34, 35, 36 bilateral carotid artery occlusion,37, 38, 39 or autologous blood injection.40 The characteristics of the included studies are shown in Table 1.

3.1.3. Fundamental study characteristics: moxibustion

The most frequently used acupoint was GV20 (11 studies), followed by GV14 (6 studies), ST36 (5 studies), then GV24 and BL23 (4 studies; Supplementary material). The extra acupoints selected for treatment are described in Supplementary material. Indirect moxibustion was used in most of the studies, except for two studies where direct moxibustion was performed.38,40 Among those that used indirect moxibustion, eight burned the moxibustion about 2–3 cm above the surface of the acupoints, four placed a moxibustion cone on the skin and burned it, and two stimulated the acupoints by dropping ashes of thread soaked in herb medicine on the acupoints. The total treatment period ranged from 2 to 11 weeks, and the most frequently set time was 4 weeks (9 studies).

3.2. Quality assessment of the included studies

3.2.1. Risk of bias

Based on the checklist for evaluating the risk of bias, on average about 5.3 criteria were satisfied by the included studies (Table 2). All studies reported the implementation of randomization and possible conflicts of interest. However, no study reported the blinding process of allocation and only one study performed the blinded assessment of outcome.

Table 2.

Risk of bias in the included studies evaluated by the CAMARADES’ study quality checklist.

(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

(10)

Total count of Y

Du 26

Y

Y

Y

N

N

Nn

Y

N

Y

Y

6

Liu 33

Y

Y

Y

N

Y

Nn

Y

N

N

Y

6

Wang 27

Y

Y

Y

N

N

Nn

Y

N

N

Y

5

Wang 28

Y

Y

Y

N

N

Nk

Y

N

Y

Y

6

Wang 29

Y

Y

Y

N

N

Nk

Y

N

Y

Y

6

Jiang31

Y

N

Y

N

N

Nk

Y

N

N

Y

4

Wang 34

Y

N

Y

N

N

Nk

Y

N

N

Y

4

Wang 37

Y

Y

Y

N

N

Nk

Y

N

Y

Y

6

Zhu 30

Y

Y

Y

N

N

Nn

Y

N

N

Y

6

Wang 35

Y

Y

Y

N

N

Nn

Y

N

Y

Y

6

Weilan38

Y

Y

Y

N

N

Nk

Y

N

Y

Y

6

Luo 40

Y

Y

Y

N

N

Nk

Y

N

N

Y

5

Zhang 36

Y

Y

Y

N

N

Nk

Y

N

N

Y

5

Xiao 7

Y

Y

Y

N

N

Nn

Y

N

N

Y

5

Yu 32

N

Y

Y

N

N

Nn

Y

N

N

Y

4

Zhu 39

N

Y

Y

N

N

Nk

Y

N

Y

Y

5

Total count of Y

14

14

16

0

1

0

16

0

7

16

Open in a new tab

(1) Publication in peer-reviewed journal (2) Statement of control of temperature (3) Randomization of treatment or control (4) Allocation concealment (5) Blinded assessment of outcome (6) Avoidance of anesthetics with marked intrinsic properties (7) Use of a suitable animal model (8) Sample size calculation (9) Statement of compliance with regulatory requirements (10) Statement regarding possible conflict of interest.

Y, Yes; N, No; Nn, Not necessary; Nk, Not known.

3.2.2. Reporting quality

Regarding the ARRIVE guidelines (Table 3), all studies fully presented four items, including the title, objectives, sample size per group, and funding. Regarding the experimental procedure, although most studies detailed “how it was conducted,” only four studies mentioned “why it was conducted.” Although all studies reported the sample size, the method and reference of sample calculation were not reported, and the assessment regarding the statistical approach was not properly disclosed.

Table 3.

Reporting quality assessment of the treatment studies based upon the ARRIVE guidelines.

Study

ARRIVE Guideline

Introduction

Methods

Results

Discussion

Title

Abstract

Back ground

Objec tives

Ethical statement

Study design

Experimental procedure

Experimental animals

Housing/ husbandry

Sample size

Allocating animals to experimental groups

Experimental outcomes

Statistical methods

Baseline data

Numbers analyzed

Outcomes and estimation

Adverse events

Interpretation/scientific implications

Generalizability / Translation

Funding

a

b

a

b

c

a

b

c

d

a

b

a

b

c

a

b

c

a

b

a

b

c

a

b

a

b

a

b

c

Du 26

F

P

F

F

F

F

F

P

P

F

P

P

N

F

P

F

F

N

F

N

NA

P

N

F

P

F

N

P

F

NA

F

N

N

F

F

P

F

F

Liu 33

F

P

F

F

F

F

F

F

F

F

F

F

F

F

F

F

F

N

F

N

NA

F

N

F

F

F

N

P

F

P

P

N

N

F

F

N

F

F

Wang 27

F

P

P

P

F

N

F

F

P

F

P

F

N

F

F

P

P

N

F

N

NA

P

N

F

P

F

N

F

F

NA

F

N

N

F

N

N

P

F

Wang 28

F

P

P

P

F

N

F

F

P

F

F

F

N

F

F

N

N

N

F

N

NA

P

N

F

P

F

N

P

F

NA

F

N

N

F

N

N

P

F

Wang 29

F

P

P

P

F

F

F

P

P

F

F

F

F

F

F

P

P

N

F

N

NA

P

N

F

F

F

N

F

F

F

F

N

N

F

N

N

P

F

Jiang31

F

P

P

P

F

F

F

F

P

F

F

F

F

F

F

F

P

P

F

N

NA

P

N

F

F

F

N

N

F

F

F

N

N

F

N

N

P

F

Wang 34

F

P

F

P

F

N

F

P

F

F

F

F

P

F

F

F

P

P

F

N

NA

F

N

F

F

F

N

N

F

F

F

N

N

P

N

N

P

F

Wang 37

F

P

F

P

F

N

F

F

F

F

F

F

N

F

F

F

P

P

F

N

NA

F

N

F

F

F

N

N

F

F

F

N

N

P

N

N

N

F

Zhu 30

F

P

F

P

F

F

F

P

F

F

F

F

N

P

F

P

P

N

F

N

NA

F

N

F

F

F

N

P

F

F

F

N

N

F

N

N

N

F

Wang 35

F

P

F

P

F

N

F

P

F

F

F

F

N

F

F

F

N

N

F

F

NA

F

N

F

NA

F

N

P

F

F

F

N

N

F

N

N

N

F

Weilan38

F

P

F

P

F

F

F

P

F

F

F

F

N

F

F

F

F

P

F

N

NA

F

N

F

F

F

N

P

F

F

F

N

N

F

N

N

P

F

Luo 40

F

P

F

P

F

N

F

F

F

F

F

F

N

F

F

F

F

P

F

N

NA

F

N

F

F

F

N

F

F

F

F

N

N

F

P

N

P

F

Zhang 36

F

P

F

P

F

N

F

F

F

F

F

F

N

F

F

F

P

P

F

N

NA

F

N

F

F

F

N

F

F

F

F

N

N

F

P

N

P

F

Xiao 7

F

P

F

P

F

N

F

P

F

F

F

F

N

F

F

P

F

P

F

N

NA

F

N

F

F

F

N

P

F

F

F

N

N

F

F

N

P

F

Yu 32

F

F

F

P

F

N

F

F

F

F

F

F

N

F

F

P

F

N

F

N

NA

F

N

F

F

F

N

P

F

NA

F

N

N

F

F

N

P

F

Zhu 39

F

F

F

P

F

F

F

F

F

F

F

F

N

F

F

P

F

N

F

N

NA

F

N

F

F

F

F

F

F

F

F

N

N

F

F

N

P

F

Open in a new tab

Abbreviations: ARRIVE, Animal Research: Reporting In Vivo Experiments; F, fully reported; P, partially reported; N, not reported; NA, not applicable.

3.2.3. Data acquisition for analysis

Regarding the analysis of the behavioral test results, we excluded studies that reported duplicated data29 or omitted detailed values33 from the outcome analysis. Furthermore, studies reporting graph-shaped results33,35,41,42 were scaled by the GetData graph digitizer program, and the means and standard deviations were extracted.

3.3. Outcome analysis of the included studies

3.3.1. Results of primary outcome: behavioral experiments

Among the studies that performed behavioral tests, those with duplicated29 and insufficient data33 were excluded, whereas results presented in the form of graphs33,35,41,42 were converted to numerical values. Consequently, we obtained results from 11 behavioral tests and finally included five studies that performed the MWM test and two that performed the step-down and nerve behavioral tests for analysis.

3.2.2. Morris water maze test

Among the nine studies that performed MWM tests, five26,30,31,36,40 that reported the individual results for MWM tests conducted for 4 days were included in the meta-analysis. Regarding escape latencies, the moxibustion group showed a significantly decreased escape latency compared to the control group after analysis of results measured from days 1 to 4 (Fig. 2). Additionally, from the 1st to the 3rd day, there was a decreasing tendency of the SMD of escape time (1st day: SMD: −1.97; 95% CI: −3.54, −0.40; p =  0.01, I2 = 90%; 2nd day: SMD: −3.19; 95% CI: −5.32, −1.06; p <  0.001, I2 = 93%; 3rd day: SMD: −4.51; 95% CI: −7.07, −1.96; p <  0.001, I2 = 93%). The greatest difference in the SMD between the moxibustion and control group was observed on the 3rd day.

Fig. 2.

Open in a new tab

Forest plot of escape latency in the Morris water maze test from the 1st to 4th day.

Regarding platform crossing times, the moxibustion group presented significantly increased crossing times compared to the control group (SMD: 4.19; 95% CI: 1.98, 6.40; p <  0.001; Fig. 3A). The dwelling time was reported in four different formats as follows: time spent in the quadrant,43,44,45 percentage of time dwelling,30,33,41,42 percentage of total distance traveled within the quadrant,46 and picture tracking of the animal’s motion.27,31 Meta-analysis indicated a significantly increased dwelling time in the quadrant in the moxibustion group compared with that in the control group (SMD: 2.49; 95% CI: −0.10, 5.07; p <  0.001); however, the heterogeneity remained high (I2 = 93%). Three studies,27,31,46 albeit not included in the meta-analysis, showed significantly decreased distance within the quadrant where animals in the moxibustion group traveled.

Fig. 3.

Open in a new tab

Forest plot of (A) cross times and dwelling time in the Morris water maze test (B) latency period and error times in the step-down test. (C) nerve behavior score.

3.2.3. Step-down test

Among the three studies that performed step-down tests, two studies34,37 reporting same methods were meta-analyzed and showed significantly extended latent periods (SMD: 2.93; 95% CI: 2.03, 3.83; p <  0.001; Fig. 3B (A)) and shortened error times (SMD: −2.50; 95% CI: −3.70, −1.31; p <  0.001; Fig. 3B (B)) in the moxibustion group.

In another study,33 the moxibustion group showed significantly prolonged latency and decreased error counts in both training and retention stages.

3.2.4. Nerve behavior score

Two of the studies34,37 that conducted step-down tests also determined nerve behavior scores. The results were scored by a five-point scale in reference to a previous study47 Consequently, we found significantly decreased nerve behavior scores in the moxibustion group compared with the control group (SMD: −2.09; 95% CI: −2.82, −1.36; p <  0.001; Fig. 3C).

3.2.5. Results of the secondary outcome: putative immunohistochemical biomarkers

Fourteen of the included studies investigated various immunohistochemical biomarkers for pathogenic characteristics (Table 4 and Fig. 4).

Table 4.

Outcomes evaluated in the included studies.

Study

Outcome

Signal pathway

Behavioral test

Du 26

1. Morris water maze a) Escape latency b) Crossing times c) Dwelling time

Apoptosis rates ↓

Liu 33

1. Morris water maze c) Dwelling time

GFAP ↓, Aβ ↓

Wang 27

1. Morris water maze a) Escape latency b) Crossing times

Bcl-2 ↑, Bax ↓, Caspase-3 ↓

Wang 28

None

Aβ ↓

Wang 29

Duplicated with Wang 27

Morphologic change

Jiang 31

1. Morris water maze b) Crossing times

IL-1β ↓, IL-2 ↑, Aβ ↓

Wang 34

2. Step-down test a) Latent period b) Error times 3. Nerve behavior score

VEGF ↑, flt-1 ↑, flk-1mRNA ↑

Wang 37

2. Step-down test a) Latent period b) Error times 3. Nerve behavior score

VEGF ↑, flt-1 ↑, bFGF ↑, bFGF-r ↑

Zhu 30

1. Morris water maze a) Escape latency b) Crossing times c) Dwelling time

PS1 ↓, BACE-1 ↓, serum IL-6 ↓, Aβ ↓

Wang 35

None

morphologic change

Weilan 38

NA

Bax ↓, Bcl-2 ↑, C-fos ↓

Luo 40

1. Morris water maze a) Escape latency b) Crossing times

NA

Zhang 36

NA

Vascular endothelial cell proliferation↑, migration↑

Xiao 7

1. Morris water maze a) Escape latency

Bax ↓, Bcl-2 ↑, SOD2 ↑, MDA ↓, GSH-Px ↑ ChAT ↑, AChE ↓

Yu 32

NA

Metabolites of TCA ↑ Metabolites of fatty acid ↓ Mono / polyunsaturated fatty acids ↑

Zhu 39

1. Morris water maze a) Escape latency

NF-κB (NF-κBp65, NFκBp50) ↓, TNF-α ↓, IL-1β ↓, morphologic change

Open in a new tab

Abbreviations: TCA, tricarboxylic acid; FA, fatty acid; P-p38 MAPK, phospho-p38 mitogen-activated protein kinase; Aβ, β-amyloid; GFAP, glial fibrillary acidic protein; IL, interleukin; VEGF, vascular endothelial growth factor; Flt-1, fms-like tyrosine kinase 1; bFGF, basic fibroblast growth factor; Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associated X protein; SOD, superoxide dismutase; MDA, malondialdehyde; BACE-1, β-site APP cleaving enzyme 1; PS1, presenilin-1; APP, Amyloid precursor protein; GSH-Px, glutathione peroxidase; AChE, acetylcholinesterase; ChAT, choline acetyltransferase; TNF-α, tumor necrosis factor-α; NF- kB, nuclear factor-kappa.

Fig. 4.

Open in a new tab

Putative mechanisms underlying cognitive impairment. The mechanisms identified in the figure represent those that could be modulated by moxibustion based on the reviewed studies.

Liu et al33 reported decreased levels of glial fibrillary acidic protein (GFAP), whereas three studies30,31,39 verified attenuated inflammatory damage after moxibustion treatment. Three studies7,27,38 demonstrated apoptosis-related factors that were controlled after moxibustion treatment; they also reported the upregulation of B-cell lymphoma 2 (Bcl-2) and downregulation of Bcl-2–associated X protein (Bax). The morphological changes of neuronal cells in the control group were compared with those of the moxibustion group,29,30 and recovery of morphological characteristics of neuronal cells was observed in the moxibustion group. Four studies28,30,31,33,41 investigated Aβ genesis and found it to be significantly restrained in the moxibustion group, with Zhu et al30 reporting decreased levels of PS1 and β-site APP cleaving enzyme 1 (BACE-1) in the moxibustion group, indicating the efficacy of moxibustion in regulating Aβ genesis.

Two studies34,37 found that moxibustion improved VEGF levels and related factors. Furthermore, Zhang et al36 postulated that proliferation and migration of vascular endothelial cells occurred in the moxibustion group. Yu32 also investigated attenuated metabolites of the TCA cycle and fatty acid metabolism after moxibustion.

4. Discussion

4.1. Summary of the main findings

The outcomes of this SR verified the efficacy of moxibustion in the treatment of cognitive impairment. Moxibustion treatment significantly improved the results of the behavioral test, the primary outcomes; it also showed efficacy against neurodegenerative disorders as shown through the outcomes of the immunohistochemical biomarkers, the secondary outcomes. These effects include attenuated acetylcholine (ACh) deficit and mitochondrial oxidative stress, attenuated inflammation and APP secretion, enhanced vascular endothelial growth factor (VEGF) activity and proliferation of vascular endothelial cells, and modulation of metabolites of the tricarboxylic acid (TCA) cycle and fatty acid metabolism.

4.2. Overall completeness and applicability of the evidence

4.2.1. Suppressing ACh deficits and mitochondrial oxidative stress

The accumulation of Aβ1–42 has been reported to ACh deficit48 related oxidative stress,49 which leads to metabolic malfunctions in the brain.50,51 Liu et al33 reported the upregulation of choline acetyltransferase (ChAT) and GSH-Px and downregulation of AChE in the moxibustion group, suggesting that moxibustion could treat cognition loss by attenuating ACh deficits and mitochondrial oxidative stress.

4.2.2. Controlling APP secretase and Aβ genesis

Since Aβ is generated from β-secretase, including BACE-1 or γ-secretase composed of PS1 or PS2,52,53 inhibiting γ- or β-secretase has been targeted for AD treatment.54 Zhu et al30 reported the downregulation of PS1 and BACE-1 after moxibustion treatment, indicating the effect of moxibustion in preventing Aβ genesis and other five studies also demonstrated reduced Aβ formation 26,28,30,33,55 by moxibustion treatment.

4.2.3. Attenuating apoptosis

Accumulated Aβ in AD and ischemia in VD are considered to induce massive neuronal apoptosis.56,57 In response to apoptotic signals, overexpressed Bax promotes cell death by antagonizing the Bcl-2 complex.58 Two studies7,27 indicated the apoptosis-suppressive effect of moxibustion by demonstrating modulated Bcl-2 and Bax in the moxibustion group. Further, Weilan et al38 reported the downregulation of C-fos protein and, two other studies26,29 demonstrated the mitigated apoptotic morphology of cells after moxibustion treatment.

4.2.4. Regulating inflammation

In response to neuronal toxicity, activated microglia and astrocytes lead to increased levels of GFAP,59,60 which is correlated with NFTs,61,62 cytokines such as interleukin (IL) and tumor necrosis factor-α (TNF-α),63 and pro-inflammatory proteins such as nuclear factor κB (NF-κb). IL-1β is genetically correlated with a high risk of AD,64 IL-6 is elevated shortly after ischemic events, while IL-2 reduces amyloid plaque load.65

Jiang et al31 proposed that moxibustion alleviated neuroinflammation based on findings of decreased IL-1β and increased IL-2 levels, which were consistent with the findings of Zhu et al,30 Liu et al,33 and Zhu et al39 regarding attenuated pro-inflammatory factors after moxibustion treatment.30,66

4.2.6. Modulating metabolites of TCA cycle and fatty acid metabolism

Deficits in mitochondrial enzymes of the TCA are related to clinical disability in AD67; meanwhile lipid metabolism malfunction can contribute to the pathogenesis68 of brain injuries and neuropsychiatric disorders.69 Yu32 observed that moxibustion increases the levels of metabolic products of the TCA cycle and fatty acid metabolism.

4.2.7. Activating the VEGF

In response to ischemia,70 the angiogenic factor VEGF induces neuroprotective effects.71 Therefore, decreased levels of VEGF cause chronic ischemia of neurons.71 Three studies demonstrated that moxibustion treatment ameliorated ischemia-driven memory loss by improving levels of VEGF and basic fibroblast growth factor and its receptor. In addition, Zhang et al36 reported the improved proliferation and migration of endothelial cells in moxibustion-treated VD rats (Fig. 4).

4.3. Potential biases in the review process

There are several limitations inducing potential biases in the review process. First, the low reporting quality reduced the credibility of the study results. Ambiguity in the model selection and outcome assessment presents a high risk of assessment bias, and insufficient reporting of excluded animals may indicate a high risk of reporting bias. Second, insufficient between-group baseline adjustments and differences in the therapeutic protocol could potentially distort the results, causing high heterogeneity between studies. Third, the obtained results were insufficient to allow generalized conclusions regarding every possible cognitive impairment condition. The small number of included studies and different reporting formats impeded the analysis of some studies, and the included animal models do not encompass all possible cognitive impairment cases.

4.4. Comparison to previous reviews and implications

Compared to our previous SR22 investigating the efficacy of moxibustion in preventing cognitive impairment, this study is more focused on the therapeutic effects of moxibustion. In both SRs, moxibustion treatment improved the behavioral test scores, and suppression of apoptosis and inflammation appeared to be the common mechanism induced by moxibustion. In preventive research, increased activity of neurotrophins, heat shock protein, and modulation of the cell cycle were demonstrated to be mediated by moxibustion; meanwhile, this study suggests modulation of metabolites and mitochondrial oxidative stress as the therapeutic mechanism of moxibustion.

4.5. Implication for clinical trials

In previous clinical studies, moxibustion treatment groups showed increased clinical scores accompanying attenuated metabolic factors including lower blood cholesterol levels,72 suppressed oxidative stress,17 and regulated balance between plasma thromboxane B2 and 6-keto-PG1α.73 These findings have a part in common with the results of the present animal SR analysis. However, there is limited direct connection. The animal model design is inherently limited in terms of interpretation and application of human pathology. Unclear understanding of the pathology of human cognitive impairment makes it difficult to implement the results from an animal model in the treatment of humans.74

Despite the limitations, animal research has played a pivotal role in understanding the biological mechanisms of cognitive diseases and evaluating the efficacy of the drugs.75 Although designing an ideal animal study and implementing a clinical study is challenging, interpreting research using various models and improved evaluation methods might be helpful in overcoming the limitations of biased analyses.

4.6. Conclusions

This SR showed that moxibustion might be beneficial in treating cognitive impairment. Its mechanism might encompass the suppression of oxidative stress and apoptosis, modulation of inflammation and Aβ genesis, enhancement of VEGF activity, and adjustment of metabolites of the TCA cycle and fatty acid metabolism. However, there were several limitations of this review, including the small number of included studies that lacked a common study design. Furthermore, the low reporting quality induced a high risk of bias and impeded the validation of the findings. More specific and rigorous trials with large sample sizes are needed to validate the efficacy of moxibustion for cognitive impairment and thoroughly examine the underlying mechanisms.